Type 2 diabetes. Diabetes mellitus due to underlying condition
Conditions
Interventions
Intervention 1: Intervention group: For patients, in addition to the drugs they receive for glycemic control, gliclazide-MR 30 mg (produced by Actoverco pharmaceutical company) twice a day will be pre
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to No maximum
Inclusion criteria
Inclusion criteria: Type 2 diabetes patients with HbA1C above 10% Age over 30 years
Exclusion criteria
Exclusion criteria: Patients with kidney and liver failure Heart failure Stroke Pregnancy Previous receipt of gliclazide and insulin Gastric problems Consumption of sulfonylureas Urine ketone positivity while having symptoms of polyuria Diabetic ketoacidosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1C. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: High Performance Liquid Chromatography(HPLC).;Fasting blood sugar (FBS). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: High Performance Liquid Chromatography (HPLC).;Two-hour blood sugar (BS 2hpp). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: High Performance Liquid Chromatography (HPLC). | — |
Secondary
| Measure | Time frame |
|---|---|
| Excessive drinking and excessive urination. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Interview.;Weight. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Weight scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Ebrahim Mohammmadi
Oroumia University of Medical Sciences
Outcome results
None listed